Pentostatin treatment combinations in chronic lymphocytic leukemia

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 6, 2009, Pages 386-392

  Lamanna, Nicole ^a   Kay, Neil E ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Clinical trials; CLL; Pentostatin; Toxicity

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALKYLATING AGENT; CHLORAMBUCIL; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; MITOXANTRONE; PENTOSTATIN; PREDNISONE; RITUXIMAB;

ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; IMMUNE DEFICIENCY; INFECTION; INFECTION COMPLICATION; LYMPHOCYTOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FORECASTING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MITOXANTRONE; MULTICENTER STUDIES AS TOPIC; PENTOSTATIN; SALVAGE THERAPY; TREATMENT OUTCOME; VIDARABINE;

EID: 70349490598     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Grever MR, Siaw MF, Jacob WF, et al. The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood. 1981;57:406-417.
2. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. J Clin Oncol. 1989;7: 433-438.
3. Ho AD, Thaler J, Stryckmans P, et al. Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst. 1990;82:1416-1420.
4. Johnson SA, Catovsky D, Child JA, Newland AC, Milligan DW, Janmohamed R. Phase I/II evaluation of pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. Invest New Drugs. 1998;16:155-160.
5. Oken MM, Lee S, Kay NE, Knospe W, Cassileth PA. Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymphoma. 2004;45:79-84.
6. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007;109:405-411.
7. Ferrajoli A, Wierda W, Lerner S, Faderl S, Kantarjian H, Keating MJ. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leukemia and Lymphoma. 2005;46(supp 1):S86.
8. Eichhorst BF, Busch R, Stauch M, et al. No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG). Blood. 2007;110:629.
9. Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007;109:2291-2298.
10. Kay N, Wu, W, Byrd JC, et al. Cyclophosphamide remains an important component of treatment in CLL patients receiving pentostatin and rituximab based chemoimmunotherapy. Blood (ASH Annual Meeting Abstracts). 2008;12:Abst 43.
11. Reynolds C, DiBella N, Lyons RM, et al. Phase III trial of fludarabine, cyclophospamide, and rituximab vs. pentostatin, cyclophosphamide and rituximab in B-cell chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts). 2008;112: Abst 327.
12. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
13. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-14.
14. Hallek M, Fingerle-Rowson G, Fink AM, et al. Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts). 2008;112:Abst 325.
15. Samaniego F, Fanale M, Pro B, et al. Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression Blood (ASH Annual Meeting Abstracts). 2008;112:Abst 835.
16. Johnston JB, Verburg L, Shore T, Williams M, Israels LG, Begleiter A. Combination therapy with nucleoside analogs and alkylating agents. Leukemia. 1994;8 Suppl 1:S140-1433.
17. Weiss MA, Maslak PG, Jurcic JG, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003;21:1278-1284.
18. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:1414-1420.
19. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006;24:1575-1581.
20. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070-4078.
21. Lamanna N, Heaney ML, Brentjens RJ, Jurcic JG, Weiss MA. Pentostatin, Cyclophosphamide, rituximab, and mitoxantrone (PCRM): A new highly active regimen for patients with chronic lymphocytic leukemia (CLL) previously treated with PCR or FCR. Blood (ASH Annual Meeting Abstracts). 2007;110:3115.
22. Kay NE, Kim HT, Kempin S, et al. Predictors of clinical outcome to pentostatin, cyclophosphamide and rituximab (PCR) followed by Campath for relapsed/refractory CLL - A study of the Eastern Cooperative Oncology Group, E2903. Blood (ASH Annual Meeting Abstracts). 2008;112:387:Abst 1057.
23. Montserrat E. Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal. J Clin Oncol. 2005;23:2884-2885.
24. Weiss MA, Glenn M, Maslak P, et al. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia. 2000;14:1577-1582.
25. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23:2971-2979.
26. Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996;88:2228-2235.